Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab + Chemo in MSS Locally Advanced Colon Cancer
NCT06124378Phase 2Active, not recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in colon cancer, sponsored by The First Affiliated Hospital of Guangxi Medical University. Started Nov 2023; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06124378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124378.